US FDA Would See Cash Windfall In COVID-19 Relief Bill
The $500m in additional funds would support pandemic-related activities, potentially for additional staff or technology upgrades.
You may also be interested in...
FDA is only mentioned once in the document, and its temporary leadership may not be the reason why.
National Academies report argues that technologies cannot only be evaluated in the context of specific products, and FDA guidance should become both ‘more fluid and targeted.’
$10bn here and $6bn there on top of what’s left from earlier CARES Act gives government more options on COVID-19 medical countermeasures.